Price
Financials
Standalone, Rs crore| Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 58 | 48 | 58 | 49 | 58 | 64 | 167 |
| Expenses | 47 | 52 | 44 | 51 | 45 | 52 | 57 | 151 |
| Operating Profit | 4 | 6 | 3 | 7 | 4 | 6 | 8 | 16 |
| OPM % | 8% | 11% | 7% | 13% | 7% | 10% | 12% | 9% |
| Other Income | 1 | 1 | 3 | 2 | 2 | 3 | 2 | 3 |
| Interest | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 4 | 6 | 5 | 8 | 4 | 6 | 7 | 16 |
| Tax % | 36% | 18% | 17% | 27% | 29% | 18% | 25% | 22% |
| Net Profit | 2 | 5 | 4 | 6 | 3 | 5 | 5 | 13 |
| EPS in Rs | 48.12 | 6.93 | 3.75 | 5.63 | 3.05 | 4.74 | 4.15 | 9.84 |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 56 | 56 | 60 | 101 | 109 | 106 | 107 | 231 |
| Expenses | 48 | 53 | 53 | 57 | 95 | 98 | 95 | 97 | 208 |
| Operating Profit | 2 | 3 | 3 | 3 | 6 | 11 | 10 | 9 | 23 |
| OPM % | 4.9% | 4.8% | 4.7% | 5% | 6% | 10% | 10% | 9% | 10% |
| Other Income | 0 | 0 | 0 | 1 | 2 | 2 | 4 | 5 | 6 |
| Interest | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 4 |
| Depreciation | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 2 |
| Profit before tax | 1 | 1 | 1 | 1 | 6 | 10 | 13 | 11 | 24 |
| Tax % | 10% | 8% | 41% | 9% | 25% | 24% | 23% | 23% | 23% |
| Net Profit | 1 | 1 | 0 | 1 | 5 | 8 | 10 | 8 | 18 |
| EPS in Rs | 50.76 | 61.02 | 27.00 | 73.43 | 248.92 | 9.95 | 9.39 | 7.79 | 13.98 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 31% | 28% | 117% | ||
| Compounded Profit Growth | % | 66% | 30% | 114% | ||
| Stock Price CAGR | % | % | 44% | 87% | ||
| Return on Equity | % | 21% | 17% | 17% |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 8 | 10 | 10 | 13 |
| Reserves | 5 | 6 | 5 | 8 | 11 | 16 | 44 | 53 | 124 |
| Borrowings | 9 | 11 | 14 | 14 | 10 | 7 | 7 | 31 | 50 |
| Other Liabilities | 12 | 14 | 23 | 15 | 32 | 34 | 38 | 54 | 87 |
| Total Liabilities | 28 | 33 | 44 | 40 | 54 | 65 | 100 | 148 | 274 |
| Fixed Assets | 7 | 8 | 10 | 11 | 12 | 13 | 18 | 40 | 53 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 0 |
| Investments | 0 | 0 | 1 | 0 | 1 | 0 | 5 | 0 | 0 |
| Other Assets | 21 | 25 | 33 | 29 | 42 | 51 | 77 | 96 | 220 |
| Total Assets | 28 | 33 | 44 | 40 | 54 | 65 | 100 | 148 | 274 |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0 | 0 | 2 | -4 | 12 | 6 | -4 | 5 | -32 |
| Cash from Investing Activity | 0 | 0 | -2 | -2 | -0 | -3 | -12 | -30 | -10 |
| Cash from Financing Activity | 0 | 0 | 2 | 5 | -8 | -1 | 21 | 22 | 76 |
| Net Cash Flow | 0 | 0 | 2 | -2 | 4 | 3 | 5 | -4 | 34 |
| Free Cash Flow | 0 | 0 | -1 | -7 | 12 | 2 | -13 | -31 | -37 |
| CFO/OP | 0% | 0% | 68% | -127% | 197% | 84% | -9% | 78% | -118% |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 35 | 36 | 35 | 26 | 56 | 58 | 75 | 70 | 106 |
| Inventory Days | 64 | 73 | 125 | 113 | 57 | 67 | 99 | 206 | 120 |
| Days Payable | 102 | 97 | 143 | 89 | 92 | 110 | 116 | 188 | 146 |
| Cash Conversion Cycle | -3 | 12 | 17 | 51 | 21 | 15 | 58 | 87 | 80 |
| Working Capital Days | 12 | 23 | -28 | 41 | -19 | 2 | 52 | 61 | 24 |
| ROCE % | 15% | 12% | 14% | 32% | 45% | 30% | 16% | 19% |
| Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | May 2026 | |
|---|---|---|---|---|---|---|---|
| Promoters | 73.56% | 73.56% | 73.56% | 73.56% | 58.90% | 58.90% | 52.83% |
| FIIs | 0.03% | 0.00% | 0.00% | 0.39% | 0.15% | 0.15% | 0.14% |
| DIIs | 4.26% | 1.97% | 1.13% | 1.11% | 10.81% | 10.73% | 19.94% |
| Public | 22.14% | 24.47% | 25.31% | 24.93% | 30.13% | 30.21% | 27.10% |
| No. of Shareholders | 722 | 1,229 | 1,248 | 1,229 | 758 | 841 | 948 |
Fundamentals
Market Cap₹ 869 Cr.
Current Price₹ 598
Stock P/E51.3
Book Value₹ 105
ROCE18.9 %
ROE16.9 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)117%
Compounded Profit Growth (TTM)114%
Standalone figures.
Valuation
Market capRs 637 Cr
Enterprise valueRs 659 Cr
P/E (TTM)78.40x
Price to book10.12x
Price to sales5.98x
EV / EBITDA46.03x
EV / EBIT51.10x
EV / sales6.18x
Price to cash flow138.86x
Earnings yield1.28%
P/E, 3-year average13.49x
P/B, 3-year average2.09x
P/E, 5-year average13.49x
P/B, 5-year average2.09x
Profitability
Operating margin (excl. other income)8.77%
Operating margin (incl. other income)13.43%
EBITDA margin13.43%
Pre-tax margin9.91%
Net profit margin7.63%
ROE13.80%
ROCE16.59%
ROA6.57%
ROE, 3-year average26.90%
ROCE, 3-year average30.53%
ROA, 3-year average10.43%
ROE, 5-year average27.08%
ROCE, 5-year average27.54%
ROA, 5-year average8.85%
ROIC (approx.)11.78%
Tax rate22.92%
Other income / net worth7.89%
Growth
Sales growth (latest year)0.87%
Profit growth (latest year)-17.04%
Sales CAGR, 3 years1.69%
Sales CAGR, 5 years13.69%
Profit CAGR, 3 years20.82%
Profit CAGR, 5 years74.67%
Per share
EPS (TTM)Rs 7.79
EPS (latest year)Rs 7.79
EPS, 3-year averageRs 9.04
EPS, 5-year averageRs 23.63
Book value per shareRs 60.34
Sales per shareRs 102.03
Cash flow per shareRs 4.40
Free cash flow per shareRs -35.44
Efficiency
Asset turnover0.72x
Fixed asset turnover2.67x
Inventory turnover1.84x
Inventory days199 days
Debtor days70 days
Debtors turnover5.24x
Creditor days146 days
Cash conversion cycle80 days
Working capital days24 days
Leverage
Total debtRs 31 Cr
Cash and bankRs 9 Cr
Net debtRs 21 Cr
Debt to equity0.49x
Net debt / EBITDA1.49x
Interest coverage5.53x
Owners' fund to total sources42.66%
Debt to assets20.89%
Cash flow
Cash from Operating Activity (latest year)Rs 5 Cr
Cash from Investing Activity (latest year)Rs -30 Cr
Cash from Financing Activity (latest year)Rs 22 Cr
Net Cash Flow (latest year)Rs -4 Cr
Free cash flow (latest year)Rs -37 Cr
FCFE (approx.: FCF + change in debt)Rs -13 Cr
Cash from ops / profit, 5 years-0.27x
Sales to cash flow23.21x
Statement figures
Net sales (TTM)Rs 107 Cr
Net sales (latest year)Rs 107 Cr
Operating profit excl. other income (latest year)Rs 9 Cr
Other income (TTM)Rs 5 Cr
EBITDA (TTM)Rs 14 Cr
PBDT (TTM)Rs 12 Cr
Profit before tax (TTM)Rs 11 Cr
Tax (latest year)Rs 2 Cr
Net profit (TTM)Rs 8 Cr
Net profit (latest year)Rs 8 Cr
Depreciation (TTM)Rs 1 Cr
Interest (TTM)Rs 2 Cr
Cost of goods sold (latest year)Rs 78 Cr
Total expenditure (latest year)Rs 97 Cr
Total income (latest year)Rs 111 Cr
Share capitalRs 10 Cr
ReservesRs 53 Cr
Shareholders' fundsRs 63 Cr
Total assetsRs 148 Cr
Net blockRs 40 Cr
Capital work in progressRs 12 Cr
InvestmentsRs 0 Cr
ReceivablesRs 20 Cr
InventoryRs 42 Cr
Other liabilitiesRs 54 Cr
Shares outstanding (crore)1.04
Ownership
Promoter holding52.83% (-20.73 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 78.4 is at the 98th percentile of its own 3.4-year range
(median 31.1, low 10.3, high 78.4).
P/B 10.12 is at the 68th percentile (median 6.19).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 543916 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -0.5% | -2.8% | +2.3 pts |
| 1 month | +65.2% | -6.8% | +72.0 pts |
| 3 months | +67.3% | -7.6% | +74.9 pts |
| 3 years | +202.2% | +14.2% | +188.1 pts |
Red flags
F-score 3 of 8| explain | Weak cash conversion Cash from operations was 26% of net profit over the last 3 years |
| explain | Share dilution Share count up 0% in a year, 5100% in three |
| explain | Debt up, profit down Borrowings up 357% while net profit fell in 2026 |
| look | Inventory outrunning sales Inventory grew 102% vs sales +1% in 2026 |
| look | Profit leans on other income Other income was 47% of pre-tax profit in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Mar 2026Sales ₹167 Cr +187.9% vs Mar 2024.
Net profit ₹13 Cr +116.7%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Poly Medicure Ltd | 16,671 | 52.1 | 12.5 % |
| Molbio Diagnostics Ltd | 14,470 | 66.6 | 18.0 % |
| Fischer Medical Ventures Ltd | 2,355 | 96.2 | 11.4 % |
| Tarsons Products Ltd | 1,754 | 148 | 4.59 % |
| Q-Line Biotech Ltd | 1,569 | 27.8 | 22.5 % |
| Laxmi Dental Ltd | 1,058 | 30.4 | 15.0 % |
| Vasa Denticity Ltd | 754 | 62.3 | 7.54 % |
| OSEL Devices Ltd | 691 | 23.6 | 24.4 % |
| Prevest Denpro Ltd | 462 | 20.5 | 24.9 % |
| QMS Medical Allied Services Ltd | 419 | 39.0 | 12.9 % |
| Nureca Ltd | 349 | 80.4 | 3.30 % |
| Aprameya Engineering Ltd | 200 | 39.7 | 12.6 % |
| Avience Biomedicals Ltd | 198 | 22.7 | 27.0 % |
| Earkart Limited | 179 | 36.3 | 17.5 % |
| Vaidya Sane Ayurved Laboratories Ltd | 176 | 19.6 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Hemant Surgical Industries Ltd?
Hemant Surgical Industries Ltd (543916) has a market capitalisation of Rs 869 Cr. at the 2026-10-01 close.
What is the P/E ratio of Hemant Surgical Industries Ltd?
Hemant Surgical Industries Ltd trades at a P/E of 51.3 on trailing twelve-month profit, at the 2026-10-01 close.
What were Hemant Surgical Industries Ltd's latest quarterly results?
In the Mar 2026 quarter, Hemant Surgical Industries Ltd sales was Rs 167 Cr (+187.9% vs Mar 2024) and net profit was Rs 13 Cr.